Caricamento...
Optimum Utilisation of Novel Antiplatelet Agents in Clinical Practice
Prasugrel and ticagrelor are two novel promising antiplatelet agents inhibiting the platelet activation via the adenosine diphosphate pathway. Both achieve a faster, more intense, and more consistent platelet inhibition than clopidogrel. Both novel antiplatelet agents have demonstrated superiority o...
Salvato in:
| Pubblicato in: | Interv Cardiol |
|---|---|
| Autori principali: | , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Radcliffe Cardiology
2014
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5844017/ https://ncbi.nlm.nih.gov/pubmed/29588796 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15420/icr.2014.9.3.164 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|